Abstract
Background: Assess baseline disease severity efficacy of levodopa-carbidopa intestinal gel(LCIG) on motor fluctuations, non-motor symptoms(NMS), axial symptoms, and quality of life(QoL) in advanced Parkinson's disease(aPD) patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
